Decoding Molecular Test Reports: What Every Clinician Needs to Know

When a molecular report lands in your inbox, the first reaction is often “what does this even mean?” In today’s world of targeted therapy, a single nucleotide can dictate the next line of treatment. If you can read the report with confidence, you can steer your patient toward the right drug faster, avoid unnecessary toxicity, and feel a little less like you’re deciphering an alien language.

Why Molecular Reports Matter Today

A decade ago, most of us relied on morphology and a handful of immunostains. Now, a tumor’s DNA profile can open doors to drugs that didn’t exist when we finished residency. The stakes are higher: insurers ask for molecular justification, patients ask for the “right” pill, and multidisciplinary tumor boards expect you to explain the numbers. Understanding the report is no longer optional; it’s a core part of modern patient care.

The Building Blocks: Genes, Variants, and Nomenclature

Gene Names

Genes are listed in capital letters—think EGFR, KRAS, BRCA1. The name tells you which protein is being examined. If you see a gene you don’t recognize, a quick look‑up in the NCBI gene database will usually clear it up. Most reports stick to the official HGNC symbols, so you won’t run into synonyms that could cause confusion.

Variant Descriptions

The heart of the report is the variant line, for example:

c.2573T>G (p.Leu858Arg).

The c. part refers to the coding DNA sequence. The numbers tell you the position, and the letters show the change (T to G).
The p. part translates that change to the protein level: leucine at position 858 becomes arginine.

If you see “p.V600E”, you’re looking at the classic BRAF mutation that drives many melanomas. The report may also include “exon 19 deletion” or “fusion”—these are structural changes that can be just as important as point mutations.

Allele Frequency

Most labs report the variant allele frequency (VAF) as a percentage. A VAF of 45% in a tumor sample often means the mutation is present in most cancer cells. A low VAF (e.g., 2%) could indicate subclonal disease, contamination, or a technical artifact. Knowing the context helps you decide whether a finding is actionable or needs confirmation.

Interpreting the Clinical Significance

Tiered Classification

Many reports use a tier system (e.g., Tier I‑IV) or the AMP/ASCO/CAP categories (Tier I–IV, Level A–D).

Tier I / Level A: Strong clinical evidence; FDA‑approved therapy or guideline‑recommended.
Tier II / Level B: Clinical evidence exists, but the drug may be off‑label or in a clinical trial.
Tier III / Level C: Preclinical data or limited case reports.
Tier IV / Level D: Unknown significance; often labeled “VUS” (variant of uncertain significance).

When you see a Tier I alteration, you can move straight to the recommended drug. Tier II may prompt a discussion about trial eligibility. Tier III and IV usually require a cautious approach—sometimes a second test or a consult with a molecular tumor board.

Therapeutic Implications

Most reports include a “Interpretation” or “Clinical Actionability” section. It will list FDA‑approved drugs, clinical trials, and sometimes resistance mutations. For example, an EGFR exon 19 deletion will be paired with first‑generation EGFR inhibitors, while a concurrent T790M mutation flags resistance and suggests a third‑generation inhibitor like osimertinib.

Resistance and Co‑Occurring Mutations

Don’t overlook additional findings. A KRAS G12C mutation in a lung adenocarcinoma may render EGFR inhibitors ineffective, even if an EGFR mutation is present. Similarly, a TP53 loss can affect prognosis but not necessarily drug choice. The report’s “Co‑mutations” list is a quick way to spot these red flags.

Practical Tips for the Busy Clinician

Start with the Summary – Most labs provide a one‑page “Key Findings” box. It tells you the actionable mutations, their tier, and suggested therapies. Use it as your roadmap.
Check the Date – Molecular knowledge evolves fast. A report from three years ago may miss newer biomarkers like NTRK fusions. If the test is older, consider reflex testing.
Know Your Lab’s Method – Next‑generation sequencing (NGS) panels vary in coverage. Some only test 50 genes; others cover 500. Understanding the panel’s limits helps you decide if a negative result truly rules out a target.
Ask for Clarification – If a term like “splice site variant” or “intronic alteration” confuses you, reach out to the molecular pathologist. We love a good question; it’s how the field moves forward.
Document the Action – When you prescribe a targeted therapy based on a molecular result, note the specific variant and tier in the chart. It makes future reviews and insurance appeals smoother.

A Little Story from the Bench

I still remember a 45‑year‑old woman with metastatic colorectal cancer who came to our tumor board with a “wild‑type KRAS” result from a 2015 panel. The oncologist was puzzled because the patient responded poorly to anti‑EGFR therapy. When we ordered a newer 324‑gene NGS test, it uncovered a KRAS G12C mutation that the old assay missed. The report flagged it as Tier II, and the patient was enrolled in a clinical trial of a KRAS G12C inhibitor. Within two months, her scans showed a dramatic shrinkage. The lesson? Even a “negative” report can be a false negative if the technology is outdated.

For forensic pathologists, integrating molecular findings with toxicology can be crucial; our guide on a rapid post‑mortem toxicology screen offers practical insights.

Bottom Line

Molecular test reports are now a routine part of patient care, but they can feel like a cryptic code. By focusing on the gene name, variant description, allele frequency, and tiered significance, you can extract the actionable information without getting lost in the details. Keep a habit of reviewing the summary first, stay aware of your lab’s panel limits, and don’t hesitate to ask the pathology team for clarification. When you do, you’ll find that the report is less a mystery and more a roadmap—one that can guide your patients to the right treatment faster and with greater confidence.